NIKKEI 225
38,580.17 +506.19 (+1.33%) HANG SENG
18,537.81 0.00 (0.00%) CRUDE OIL
79.75 +0.49 (+0.62%) GOLD FUTURES
2,362.20 +21.90 (+0.94%) DOW
39,387.76 +331.36 (+0.85%) Bitcoin GBP
50,148.57 +1,082.61 (+2.21%)
Adverum Biotechnologies, Inc. (ADVM)
After hours:
- GlobeNewswire
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights
- Phase 2 LUNA interim analysis to be presented at ASRS Annual Scientific Meeting on July 17th, 2024 in Stockholm, Sweden - $193.3 million in cash, cash equivalents and short-term investments expected to fund operations into late 2025 REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today reported financial results for the
- Zacks
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
Here is how Ligand Pharmaceuticals (LGND) and Adverum Biotechnologies (ADVM) have performed compared to their sector so far this year.
- GlobeNewswire
Adverum Biotechnologies to Participate in Upcoming May Investor Conferences
REDWOOD CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will present at the following upcoming investor conferences: 2024 RBC Global Healthcare Conference on Tuesday, May 14, 2024 at 4:05 p.m. ET.BofA Securities 2024 Health Care Conference on Wednesday, May 16, 2024 at 3:40 p.m. PT.H.C. Wainwright
